What is Nuvation Bio's license — deferred revenue?

Nuvation Bio (NUVB) reported license — deferred revenue of $58.7M in Q1 2026.

What does license — deferred revenue mean?

This metric represents the deferred revenue or performance obligations arising from licensing contracts where consideration has been received but the associated performance obligations have not yet been satisfied. It serves as a measure of future revenue that is expected to be recognized as the company fulfills its contractual commitments. This liability provides insight into the long-term service or development obligations tied to existing partnership agreements.

Nuvation Bio NUVB License — Deferred Revenue

Other product segments

Research And Development Service Revenue

$18.4M+9,100%

Royalty Revenue

$300K—

Product Revenue

$100K—

Similar metrics at other companies

PRAXLicense — Contract with customer, liability, revenue recognized

$0—

SIGOther Deferred Revenue — Contract with Customer, Liability

$86.5M+6.9%

TVTXLicense and collaboration revenue — Contract with Customer, Liability, Revenue Recognized

$718K-50.9%

CNKOther Deferred Revenues — Deferred Revenue

$272.6M+5.7%

TNLDeferred other revenue — Contract with Customer, Liability

$11M+175%

VACContract With Customer, Liability, Deferred Revenue And Other

$466M—

Other financials

Income statement

See full

Revenue$83.2M+2,599%

Gross profit$9.8M+1,340%

Operating income$3.9M+107%

Net income$5.4M+110%

EPS (diluted)$0.01+106%

Balance sheet

See full

Cash & equivalents$125.4M+161%

Total debt$57.2M+401%

Total equity$319.6M-23.8%

Total assets$610.2M+23.9%

Cash flow

See full

Operating cash flow$5.1M+112%

CapEx$48.0K-33.3%

Free cash flow$5.0M+112%

Valuation

See full

Market cap$2.25B+150%

Profitability

See full

Gross margin54.3%+39.5pp

Operating margin-105%-52.0pp

Net margin-102.1%-50.6pp

FCF margin-93.5%-45.2pp

Returns & leverage

See full

Return on equity-39.5%-15.8pp

Debt / equity0.2×+0.2×

Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.

The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's license — deferred revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nuvation Bio's license — deferred revenue?: Nuvation Bio (NUVB) reported license — deferred revenue of $58.7M in Q1 2026.
What does license — deferred revenue mean?: This metric represents the deferred revenue or performance obligations arising from licensing contracts where consideration has been received but the associated performance obligations have not yet been satisfied. It serves as a measure of future revenue that is expected to be recognized as the company fulfills its contractual commitments. This liability provides insight into the long-term service or development obligations tied to existing partnership agreements.